Jair Munoz Mendoza, MD
Nephrology · Miami, FLNPI 1174752877
Payments from drug & device makers
Across 9 payments — averaging $745.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$6K
- OPKO Pharmaceuticals, LLC$234
- Bayer$151
- Baxter Healthcare$123
- Calliditas Therapeutics US Inc.$66
- Novo Nordisk$44
- plus $25 from 1 others
Across 1 payment — averaging $6070.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ardelyx, Inc.$6K
What the payments were for
- Food & beverage$61796%
- Education$254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 1 | $6,070 |
| OPKO Pharmaceuticals, LLC | 2 | $234 |
| Bayer | 2 | $151 |
| Baxter Healthcare | 1 | $123 |
| Calliditas Therapeutics US Inc. | 1 | $66 |
| Novo Nordisk | 1 | $44 |
| Akebia Therapeutics Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rayaldee$213
- Renal - PD$123
- Kerendia$109
How this compares
$6,712 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 17 | $27,398 |
| FarxigaDapagliflozin Propanediol | 13 | $7,449 |
| ClinisolParenteral Amino Acid 15% No.5 | 12 | $3,938 |
| ProsolParenteral Amino Acid 20% No.1 | 15 | $3,168 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 13 | $2,273 |
| Bumetanide | 17 | $1,001 |
| Nifedipine ErNifedipine | 32 | $720 |
| Chlorthalidone | 20 | $305 |
| Furosemide | 28 | $247 |
| Amlodipine Besylate | 39 | $238 |
| Doxazosin Mesylate | 21 | $234 |
| Losartan Potassium | 16 | $64 |
| Lisinopril | 16 | $51 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Miami
- Oscar GalvezMiami$14.2M
- Juan FernandezMiami$2.5M
- Alessia FornoniMiami$2.1M
- Hassan AliMiami$1.4M
- Shadi TaraziMiami$739K
- Fernando TrespalaciosMiami$626K
- Manuel Garcia-EstradaMiami$476K
- Anne Marie MilesMiami$419K
- Gabriel ContrerasMiami$266K
- Jose Cardona-GuzmanMiami$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.